Cellanome engages in cutting-edge synthetic biology and informatics methods through its multi-omics platform.
Cellanome has raised $150.0M in total funding. The most recent round was Series B. The last funding was announced in January 2024.
Cellanome's investors include Premji Invest, Synetro Group.
Cellanome is headquartered in Redwood City, United States.
Cellanome engages in cutting-edge synthetic biology and informatics methods through its multi-omics platform.
Cellanome is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cellanome — Funding & Investors." VCBacked, January 29, 2024, https://www.vcbacked.co/company/cellanome. Accessed August 4, 2026.
VCBacked. (2024). Cellanome — Funding & Investors. Retrieved August 4, 2026, from https://www.vcbacked.co/company/cellanome
{{cite web |title=Cellanome — Funding & Investors |url=https://www.vcbacked.co/company/cellanome |website=VCBacked |access-date=August 4, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated